BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8685955)

  • 1. Induction of chemokine gene expression during allogeneic skin graft rejection.
    Kondo T; Novick AC; Toma H; Fairchild RL
    Transplantation; 1996 Jun; 61(12):1750-7. PubMed ID: 8685955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibility-disparate skin grafts.
    Watarai Y; Koga S; Paolone DR; Engeman TM; Tannenbaum C; Hamilton TA; Fairchild RL
    J Immunol; 2000 Jun; 164(11):6027-33. PubMed ID: 10820287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts.
    Fairchild RL; VanBuskirk AM; Kondo T; Wakely ME; Orosz CG
    Transplantation; 1997 Jun; 63(12):1807-12. PubMed ID: 9210509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell-dependent acceleration of chemoattractant cytokine gene expression during secondary rejection of allogeneic skin grafts.
    Kondo T; Watarai Y; Novick AC; Toma H; Fairchild RL
    Transplantation; 1997 Mar; 63(5):732-42. PubMed ID: 9075847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early increased chemokine expression and production in murine allogeneic skin grafts is mediated by natural killer cells.
    Kondo T; Morita K; Watarai Y; Auerbach MB; Taub DD; Novick AC; Toma H; Fairchild RL
    Transplantation; 2000 Mar; 69(5):969-77. PubMed ID: 10755559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection.
    Morita K; Miura M; Paolone DR; Engeman TM; Kapoor A; Remick DG; Fairchild RL
    J Immunol; 2001 Sep; 167(5):2979-84. PubMed ID: 11509648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential chemokine gene expression in corneal transplant rejection.
    Yamagami S; Miyazaki D; Ono SJ; Dana MR
    Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2892-7. PubMed ID: 10549649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I-TAC is a dominant chemokine in controlling skin intragraft inflammation via recruiting CXCR3+ cells into the graft.
    Li B; Xu W; Xu L; Jiang Z; Wen Z; Li K; Xiong S
    Cell Immunol; 2010; 260(2):83-91. PubMed ID: 19875106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig.
    Koga S; Auerbach MB; Engeman TM; Novick AC; Toma H; Fairchild RL
    J Immunol; 1999 Nov; 163(9):4878-85. PubMed ID: 10528189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine expression in nerve allografts.
    Midha R; Munro CA; Ramakrishna V; Matsuyama T; Gorczynski RM
    Neurosurgery; 2004 Jun; 54(6):1472-8; discussion 1478-9. PubMed ID: 15157305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ T cells produce RANTES during acute rejection of murine allogeneic skin grafts.
    Koga S; Novick AC; Toma H; Fairchild RL
    Transplantation; 1999 Mar; 67(6):854-64. PubMed ID: 10199734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4 deficiency prevents eosinophilic rejection and uncovers a role for neutrophils in the rejection of MHC class II disparate skin grafts.
    Surquin M; Le Moine A; Flamand V; Rombaut K; Demoor FX; Salmon I; Goldman M; Abramowicz D
    Transplantation; 2005 Nov; 80(10):1485-92. PubMed ID: 16340795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early up-regulation of CXC-chemokine expression is associated with strong cellular immune responses to murine skin xenografts.
    Lee EM; Park JO; Kim D; Kim JY; Oh KH; Park CG; Oh BH; Kim S; Ahn C
    Xenotransplantation; 2006 Jul; 13(4):328-36. PubMed ID: 16768726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of chemokines and chemokine receptors to the rejection of fetal proislet allografts.
    Solomon MF; Kuziel WA; Simeonovic CJ
    Cell Transplant; 2004; 13(5):503-14. PubMed ID: 15565863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma is necessary for initiating the acute rejection of major histocompatibility complex class II-disparate skin allografts.
    Ring GH; Saleem S; Dai Z; Hassan AT; Konieczny BT; Baddoura FK; Lakkis FG
    Transplantation; 1999 May; 67(10):1362-5. PubMed ID: 10360591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection.
    Zhang Z; Kaptanoglu L; Tang Y; Ivancic D; Rao SM; Luster A; Barrett TA; Fryer J
    Gastroenterology; 2004 Mar; 126(3):809-18. PubMed ID: 14988835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of parathyroid graft rejection suggests alloantigen-specific production of nitric oxide by iNOS-positive intragraft macrophages.
    Matuschek A; Ulbrich M; Timm S; Schneider M; Thomas Germer C; Ulrichs K; Otto C
    Transpl Immunol; 2009 Sep; 21(4):183-91. PubMed ID: 19409993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection.
    Haskova Z; Sproule TJ; Roopenian DC; Ksander AB
    Transplantation; 2003 Apr; 75(8):1368-74. PubMed ID: 12717232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monokine induced by interferon-gamma (MIG/CXCL9) is derived from both donor and recipient sources during rejection of class II major histocompatibility complex disparate skin allografts.
    Auerbach MB; Shimoda N; Amano H; Rosenblum JM; Kish DD; Farber JM; Fairchild RL
    Am J Pathol; 2009 Jun; 174(6):2172-81. PubMed ID: 19389928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic antagonism of Mig inhibits cellular infiltration and promotes survival of class II MHC disparate skin allografts.
    Kobayashi H; Novick AC; Toma H; Fairchild RL
    Transplantation; 2002 Aug; 74(3):387-95. PubMed ID: 12177619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.